Skip to main content

Opthea Limited (OPT)

NASDAQ: OPT · IEX Real-Time Price · USD
7.05 -0.48 (-6.37%)
Sep 24, 2021 1:52 PM EDT - Market open
Market Cap310.08M
Revenue (ttm)228,254
Net Income (ttm)n/a
Shares Out42.21M
EPS (ttm)-1.14
PE Ration/a
Forward PE6.73
Dividendn/a
Ex-Dividend Daten/a
Volume1,990
Open7.65
Previous Close7.53
Day's Range7.05 - 7.65
52-Week Range6.41 - 16.23
Beta-0.07
Analystsn/a
Price Target39.97 (+467.0%)
Est. Earnings Daten/a

About OPT

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ...

IndustryBiotechnology
IPO DateOct 16, 2020
CEOMegan Baldwin
CountryAustralia
Stock ExchangeNASDAQ
Ticker SymbolOPT
Full Company Profile

Financial Performance

In 2020, Opthea's revenue was 87,075, a decrease of -45.26% compared to the previous year's 159,064. Losses were -16.53 million, -20.95% less than in 2019.

Financial numbers in millions AUDFinancial Statements

News

Opthea To Present at September Investor Conferences

MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...

3 weeks ago - GlobeNewsWire

Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD)

3 weeks ago - GlobeNewsWire

Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

1 month ago - GlobeNewsWire

Why Opthea Stock Skyrocketed Today

The big gain appears to be a sympathy move related to positive news for another drugmaker.

3 months ago - The Motley Fool

Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors

MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

3 months ago - GlobeNewsWire

Opthea Company Secretary Resignation

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Co...

5 months ago - GlobeNewsWire

Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD

MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

5 months ago - GlobeNewsWire

Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD

MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...

6 months ago - GlobeNewsWire

Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...

6 months ago - GlobeNewsWire

Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD

MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

7 months ago - GlobeNewsWire

Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

7 months ago - GlobeNewsWire

U.S. IPO Weekly Recap: Solar Technology Shines In A 9-IPO Week

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

11 months ago - Seeking Alpha

Opthea Announces Pricing of Initial Public Offering in the United States

MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

11 months ago - GlobeNewsWire

Opthea IPO: What Investors Should Know About The Genentech, Regeneron Challenger

Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea Ltd (NASDAQ...

11 months ago - Benzinga

Opthea Readies Plan For U.S. IPO

Opthea has filed proposed terms to raise capital from a U.S. IPO.

11 months ago - Seeking Alpha